Literature DB >> 6306376

Functional supersensitivity of CNS alpha 1-adrenoceptors following chronic antidepressant treatment.

D B Menkes, J H Kehne, D W Gallager, G K Aghajanian, M Davis.   

Abstract

Chronic but not acute administration (21 days) of desipramine (10 mg/kg), amitriptyline (10 mg/kg) or iprindole (5 mg/kg) enhanced the stimulatory effect of the alpha 1-adrenergic agonist phenylephrine on the acoustic startle reflex when phenylephrine was infused into the subarachnoid space of the spinal cord. Comparable supersensitivity to phenylephrine also occurred 1 week after selective depletion of norepinephrine in the spinal cord via intrathecal administration of 6-hydroxydopamine. Behavioral supersensitivity to phenylephrine was associated with an increase in the number of 3H-prazosin binding sites following denervation but not following chronic antidepressant treatments. The results indicate that chronic antidepressant treatments may enhance functional alpha 1-adrenergic transmission through mechanisms different than those following denervation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6306376     DOI: 10.1016/0024-3205(83)90411-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  11 in total

Review 1.  Rate-dependent behavioral effects of stimulation of central motoric alpha(1)-adrenoceptors: hypothesized relation to depolarization blockade.

Authors:  Eric A Stone; David Quartermain
Journal:  Psychopharmacology (Berl)       Date:  2005-01-12       Impact factor: 4.530

Review 2.  Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system.

Authors:  G B Baker; A J Greenshaw
Journal:  Cell Mol Neurobiol       Date:  1989-03       Impact factor: 5.046

3.  Effects of the phosphodiesterase inhibitor rolipram on the acoustic startle response in rats.

Authors:  J H Kehne; N M Boulis; M Davis
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  The effects of alaproclate on the pupillary responses to tyramine, phenylephrine and pilocarpine in depressed patients.

Authors:  C Thompson; S A Checkley
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

5.  Noradrenaline-stimulated inositol phospholipid breakdown as a measure of alpha 1-adrenoceptor function in rat hippocampal miniprisms after repeated antidepressant treatment.

Authors:  C J Fowler; W Danysz; T Archer
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

6.  Chronic treatment with the potential antidepressant drug rolipram: the effect on the behavioural responses to adrenergic and dopaminergic receptor agonists with some biochemical correlates.

Authors:  E Przegaliński; L Baran; J Siwanowicz; G Nowak; L Antkiewicz-Michaluk; J Vetulani
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

7.  Evaluation of the levels of free and total amitriptyline and metabolites in the plasma and brain of the rat after long-term administration of doses used in receptor studies.

Authors:  P Baumann; J M Gaillard; M Jonzier-Perey; C Gerber; C Bouras
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Behavioral evidence implicating dopamine in sensorimotor arousal and norepinephrine in the sedative effects of antidepressant drugs.

Authors:  L Kokkinidis; B D McCarter
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Assessment of rat brain alpha 1-adrenoceptor binding and activation of inositol phospholipid turnover following chronic imipramine treatment.

Authors:  P P Li; J J Warsh; D Sibony; A Chiu
Journal:  Neurochem Res       Date:  1988-12       Impact factor: 3.996

10.  alpha(1A)- and alpha(1B)-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse.

Authors:  Van A Doze; Evelyn M Handel; Kelly A Jensen; Belle Darsie; Elizabeth J Luger; James R Haselton; Jeffery N Talbot; Boyd R Rorabaugh
Journal:  Brain Res       Date:  2009-06-18       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.